Phase 2 Liver Cancer Trial, Recruiting NCT05751343 Sponsor: Sun Yat-sen University Condition: Liver Cancer
Back to Liver Cancer

Phase 2 Liver Cancer Trial, Recruiting

NCT05751343
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with liver cancer (hepatocellular carcinoma) that cannot be removed by surgery and has reached an advanced stage
  • Your liver is functioning at a reasonable level, classified as Child-Pugh A or B (confirm with trial site)
  • You are generally able to carry out daily activities with little or no limitation, rated 0 or 1 on a standard activity scale
  • Your blood test results show acceptable levels of white blood cells, infection-fighting cells (neutrophils), platelets, and hemoglobin (confirm with trial site for exact values)

Who may not be able to join:

  • You have a serious heart, lung, or kidney condition
  • You have been diagnosed with a second, separate type of cancer at some point
  • You have a medical reason why you cannot take either of the two study medications — atezolizumab or bevacizumab (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
9 March 2023
Est. completion
28 August 2024

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Objective response rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov